共 50 条
- [41] Early detection of disease recurrence in stage II and III breast cancer with Vitros CA 15-3 assay serial monitoring.CLINICAL CHEMISTRY, 2000, 46 (06) : A166 - A167Fritsche, HAGornet, TSullivan, SMcCormack, RT
- [42] Minimal residual disease (MRD) detection using a tumour naive circulating tumour DNA (ctDNA) assay in patients (pts) with resected colorectal cancer (CRC) in the phase III ASCOLT trialANNALS OF ONCOLOGY, 2023, 34 : S426 - S427Day, D.Starus, A.Gebski, V.Simes, J.Hayes, T.Padinharakam, S.Strickland, A. H.Briscoe, K.Varma, S.Barnet, M.Jackson, C.Horvath, L. G.Price, T. J.Tebbutt, N.Karki, B.Diakos, C. I.Chia, J.Toh, H. C.Jones, F. S.Segelov, E.
- [43] Minimal residual disease (MRD) detection in colorectal cancer (CRC) using a plasma-only integrated genomic and epigenomic circulating tumor DNA (ctDNA) assayANNALS OF ONCOLOGY, 2020, 31 : S419 - S419Parikh, A.van Seventer, E.Boland, G.Siravegna, G.Hartwig, A.Jaimovich, A.Raymond, V. M.Talasaz, A.Corcoran, R. B.
- [44] Detection and Quantification of ctDNA for Longitudinal Monitoring of Treatment in Non-Small Cell Lung Cancer Patients Using a Universal Mutant Detection Assay by Denaturing Capillary ElectrophoresisPATHOLOGY & ONCOLOGY RESEARCH, 2022, 28Benesova, LuciePtackova, RenataHalkova, TerezaSemyakina, AnastasiyaSvaton, MartinFiala, OndrejPesek, MilosMinarik, Marek
- [45] From liquid biopsy to cure: Using CtDNA detection of minimal residual disease to identify patients for curative therapy after non-small cell lung cancer (NSCLC) resectionJOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S736 - S736Kelly, D. C.Le, L. W.Law, J.Stockley, T.Waddell, T.Bratman, S.Leighl, N.
- [46] Detection of homologous recombination deficiency (HRD) using a novel genomic and epigenomic liquid biopsy assay in patients with breast cancer.JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)Barbacioru, CatalinYen, JenniferTolkunov, DenisSafabakhsh, PegahWang, HaoGross, AndrewOverstreet, BrookeJenkins, ColbyDrusbosky, LeylahKiedrowski, Lesli AnnEagle, CraigChuang, Han-Yu
- [47] Post resection circulating residual disease monitoring in early stage lung and colorectal cancer patients using a circulating cell-free DNA assay with ultra-high accuracy and specificity.JOURNAL OF CLINICAL ONCOLOGY, 2017, 35Maslan, AnnieJaimovich, ArielRajagopalan, NarsiTan, MichelleMortimer, StefanieChudova, DaryaKennedy, DrewKim, Hee CheolKim, Seung TaeLee, Se-HoonLee, JeeyunEltoukhy, HelmyKim, JhingoolTalasaz, AmirAli
- [48] Analysis of ctDNA for the detection of minimal residual disease (MRD) using a tissue-free, epigenomic assay in patients with early-stage breast cancer - results from the Success A studyONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 261 - 261Friedl, Thomas W. P.Rack, BrigitteFasching, Peter AndreasHartkopf, AndreasTesch, HansLorenz, RalfHeinrich, GeorgBlohmer, Jens-UweFehm, TanjaMueller, VolkmarSchneeweiss, AndreasBeckmann, MatthiasRuebner, MatthiasHarbeck, NadiaPantel, KlausDustin, DerekCai, MingyangJanni, Wolfgang
- [49] Efficacy of liquid biopsy for disease monitoring and early prediction of tumor progression in EGFR mutation-positive non-small cell lung cancerPLOS ONE, 2022, 17 (04):Ho, Hsiang-LingJiang, YuqiuChiang, Chi-LuKarwowska, SylwiaYerram, RangaSharma, KeertiScudder, SidneyChiu, Chao-HuaTsai, Chun-MingPalma, John F.Sharma, AbhaChou, Teh-Ying
- [50] Development of a liquid biopsy based purely quantitative digital droplet PCR assay for detection of MLH1 promoter methylation in colorectal cancer patientsBMC Cancer, 21Danyi WangDennis O’RourkeJorge F. Sanchez-GarciaTi CaiJuergen ScheuenpflugZheng Feng